Sugi Predict

Sugi Predict / Compounds / SCHEMBL19635138

SCHEMBL19635138

SCHEMBL19635138

CN(CCCCBr)C(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA14 Q9ULX7 2/20 0.40
▸ HDAC6 Q9UBN7 2/20 0.37
▸ HDAC1 Q13547 1/20 0.37
▸ HDAC2 Q92769 1/20 0.37
▸ CTSK P43235 3/20 0.36
▸ GBA1 P04062 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ PDK2 Q15119 1/20 0.33
▸ FPR3 P25089 1/20 0.33
▸ FPR2 P25090 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ AAK1 Q2M2I8 1/20 0.32
▸ METAP2 P50579 1/20 0.32
▸ TRPV4 Q9HBA0 1/20 0.31
▸ CACNA1G O43497 1/20 0.30
▸ CACNA1B Q00975 1/20 0.30
▸ CACNA1C Q13936 1/20 0.30
▸ CA12 O43570 1/20 0.30
▸ CA1 P00915 1/20 0.30
▸ CA7 P43166 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23971247 0.98 HDAC6 (0.39) CA14HDAC6HDAC1HDAC2CTSK
SCHEMBL18906908 0.98 HDAC6 (0.39) CA14HDAC6HDAC1HDAC2CTSK
SCHEMBL19635933 0.98 HDAC6 (0.39) CA14HDAC6HDAC1HDAC2CTSK
SCHEMBL4907545 0.94 HDAC6 (0.38) CA14HDAC6HDAC1HDAC2CTSK
SCHEMBL2682850 0.86 HDAC6 (0.36) CA14HDAC6HDAC1HDAC2CTSK
SCHEMBL28996647 0.86 CA14 (0.46) CA14HDAC6HDAC1HDAC2CTSK
SCHEMBL27006856 0.84 CA14 (0.38) CA14HDAC6HDAC1HDAC2CTSK
SCHEMBL2478206 0.83 TDP1 (0.44) CA14HDAC6HDAC1HDAC2CTSK
SCHEMBL19153077 0.83 CA14 (0.41) CA14HDAC6HDAC1HDAC2L3MBTL1
SCHEMBL3161597 0.83 CA14 (0.41) CA14HDAC6HDAC1HDAC2CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12544448-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2026-02-10 — — US disclosed
EP-4581025-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Auron Therapeutics, Inc. (US) 2025-07-09 — — EP disclosed
US-20250108117-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-04-03 — — US disclosed
US-12187746-B2 C26-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2025-01-07 — — US disclosed
US-12152041-B2 Macrocyclic fluorine substituted indole derivatives THE BROAD INSTITUTE, INC. (US) 2024-11-26 — — US disclosed
US-20240294499-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2024-09-05 — — US disclosed
EP-3788050-B1 C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS REVOLUTION MEDICINES INC (US) 2024-08-28 — — EP disclosed
US-12048749-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2024-07-30 — — US disclosed
US-20240166667-A1 C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2024-05-23 — — US disclosed
US-11976083-B2 Inhibitors of peptidylarginine deiminases GILEAD SCIENCES, INC. (US) 2024-05-07 — — US disclosed
EP-3458459-B1 MACROCYCLIC INDOLE DERIVATIVES BAYER AG (DE) 2022-04-27 — — EP disclosed
US-11286263-B2 Macrocyclic fluorine substituted indole derivatives THE BROAD INSTITUTE, INC. (US) 2022-03-29 — — US disclosed
US-11286263-B2 Macrocyclic fluorine substituted indole derivatives THE BROAD INSTITUTE, INC. (US) 2022-03-29 — — US disclosed
WO-2021222353-A1 MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2021-11-04 — — WO disclosed
CN-109715632-B Macrocyclic indole derivatives 拜尔公开股份有限公司 2021-10-26 — — CN disclosed
US-20210277022-A1 MACROCYCLIC CHLORINE SUBSTITUTED INDOLE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-09-09 — — US disclosed
US-10981932-B2 Macrocyclic indole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2021-04-20 — — US disclosed
US-20210079018-A1 MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-03-18 — — US disclosed
CN-109715632-A Macrocyclic indole derivatives 拜尔公开股份有限公司 2019-05-03 — — CN disclosed
WO-2017198341-A1 MACROCYCLIC INDOLE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2017-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12152041-B2 Macrocyclic fluorine substituted indole derivatives FOXM1, CCNT2, CCND2 CA14 4686/4885HDAC6 1938/4885HDAC1 1030/4885
US-11286263-B2 Macrocyclic fluorine substituted indole derivatives FOXM1, CCNT2, CCND2 CA14 4686/4885HDAC6 1938/4885HDAC1 1030/4885
US-20250108117-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors MTOR, RICTOR, RPTOR CA14 4004/4885HDAC6 338/4885HDAC1 526/4885
US-12048749-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR CA14 4004/4885HDAC6 338/4885HDAC1 526/4885
US-20240294499-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN MCL1, MDM2, XIAP CA14 4041/4885HDAC6 344/4885HDAC1 294/4885
US-12187746-B2 C26-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR CA14 4708/4885HDAC6 513/4885HDAC1 695/4885
US-11976083-B2 Inhibitors of peptidylarginine deiminases PADI4, PADI2, PADI1 CA14 3038/4885HDAC6 711/4885HDAC1 712/4885
US-20240166667-A1 C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS MTOR, RICTOR, RPTOR CA14 4708/4885HDAC6 513/4885HDAC1 695/4885
US-10981932-B2 Macrocyclic indole derivatives CCND2, IDO1, CCNT2 CA14 4724/4885HDAC6 1577/4885HDAC1 710/4885
US-20210079018-A1 MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES FOXM1, CCNT2, CCND2 CA14 4686/4885HDAC6 1938/4885HDAC1 1030/4885
US-20210277022-A1 MACROCYCLIC CHLORINE SUBSTITUTED INDOLE DERIVATIVES CCNT2, CCNL2, CCND2 CA14 3654/4885HDAC6 1701/4885HDAC1 1264/4885
US-12544448-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors RICTOR, MTOR, MLST8 CA14 4160/4885HDAC6 1685/4885HDAC1 2841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.